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1. Introduction
Lysosomes are found in all eukaryotic cell types,
and function as organelles specialised in protein
degradation. A series of hydrolases packaged within
the lysosomes are able to degrade proteins delivered
to this acidic compartment. Proteins can be delivered
to the lysosome via both biosynthetic and endocytic
routes. In addition, lysosomes are able to engulf other
intracellular organelles by a process called au-
tophagy.
Proteins delivered to lysosomes are rapidly de-
graded, and these organelles form an essential part in
maintaining proper function in all cell types. In the
majority of cells the lysosome functions only as an
intracellular organelle. However, in cytotoxic T lym-
 .phocytes CTL and a small number of other cell
types, the lysosome is also a secretory organelle that
contains specialised secretory proteins in addition to
the lysosomal hydrolases. In the case of CTL, the
secretory proteins are specialised for the destruction
of other cells: so that by secreting it’s lysosomal
contents the CTL is now able to kill other cells.
These specialised lysosomes of the CTL are known
as lytic granules. They are dual functional organelles
which can not only degrade proteins targeted to them
within the cell, but can also destroy whole cells as a
consequence of their secretion. This article reviews
what is known about the specialised lysosomes of
CTL and the mechanisms that are required to modify
an intracellular lysosome into a destructive secretory
granule.
2. CTL function and biochemistry
2.1. The function of CTL
CTL represent the body’s primary defence against
viral-infected and tumourigenic cells and are in-
volved in autoimmune disorders and transplant rejec-
tion. These functions are possible because of the
ability of CTL to recognise other cells as ‘‘foreign’’
and destroy them. Most cells within the body present
fragments of proteins, generated within the cell, on
the cell surface in the context of the Major Histocom-
 .  w x.patibility Complex MHC proteins reviewed 1 .
The MHC proteins are highly polymorphic enabling
CTL to distinguish between self and non-self MHC.
The MHC-peptide complex serves as an indicator of
 . both cell type self or foreign and cell status ‘‘nor-
.mal’’ or transformedrinfected . Thus, CTL patrol the
body to check for foreign cells, by engaging MHC-
 .peptide complexes with the T cell receptor TcR .
Normal self cells are ‘‘ignored’’ during this process -
they do not activate the CTL and therefore are al-
lowed to live. However, as a result of either transfor-
mation or viral infection, non-self proteins are pre-
sented in conjunction with a cell’s MHC proteins,
and this cell is subsequently recognised as foreign by
the CTL. Once activated, the CTL is able to initiate a
series of events which culminate in death of the
recognised cell. Should a CTL be able to recognise a
self protein-MHC complex, autoimmune disorders
may ensue, in which CTL destroy normal self cells.
Alternatively, if cells presenting non-self-MHC pro-
teins are introduced to the body, for example during
organ transplantation, these cells can also be recog-
nised as foreign and destroyed.
2.2. Mechanisms of killing
Following recognition of a target cell through the
TcR, a number of signals, including protein tyrosine
phosphorylation and elevation of intracellular cal-
 w x.cium levels reviewed 2 , are generated within the
CTL. These signals culminate in the induction of
transcription of the effector proteins and, after several
days, the appearance of electron-dense granules within
the CTL. The effector proteins are the mediators of
CTL function and are stored within the granules until
required. Subsequent interaction with a target cell
results in polarisation of the Golgi apparatus and the
microtubule organising centres of the CTL towards
w xthe point of contact with the target cell 3–6 , and
directed exocytosis of the granules towards the target
cell. During granule-mediated killing, the cytolytic
proteins released from the granules inflict a ‘‘lethal
 .hit’’ on the target cell and the cell dies Fig. 1 .
Alternatively, CTL may utilise a cell surface re-
ceptor to induce target cell death. A number of cell
types express a surface protein called FasrAPO-
1rCD95 which contains a ‘‘death domain’’ in its
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Fig. 1. Mechanisms of CTL-mediated cytotoxicity. At least two
cytolytic mechanisms are used by CTLs to destroy target cells.
Recognition of a foreign MHC-peptide complex through the T
 .cell receptor TcR initiates signals within the CTL that result in
transcriptional activation of function-related genes. Perforin and
the granzymes are stored in lytic granules within the CTL. Upon
further stimulation of the TcR, lytic granules are exocytosed
towards the target cell. Perforin forms a pore in the target cell
membrane, allowing the granzymes to enter the target cell and
induce death. During Fas-mediated cytotoxicity, TcR stimulation
results in upregulated FasL expression on CTL surfaces. FasL
cross-links Fas on the target cell. A death-inducing signalling
 .complex DISC is recruited to the cytoplasmic tail of Fas,
resulting in transduction of a death signal to the target cell.
w xcytoplasmic region 7 . During CTL activation, levels
 .of a protein named Fas-ligand FasL are upregulated
on the CTL surface. FasL can cross-link target cell
Fas receptors, and the oligomerised receptors can
then transduce a death signal to the target cell through
w xa number of associated proteins 8,9 . Following the
initial interaction, which results in FasL expression,
no further specific recognition of the target cell
through TcR is required for Fas-mediated cytotoxic-
ity. Thus, a FasL bearing CTL is able to destroy any
Fas-positive cell, whether it has been specifically
recognised or not. The two mechanisms used by CTL
to destroy target cells are summarised in Fig. 1.
While the granule-mediated pathway seems to be
primarily involved in the elimination of cells which
have been recognised as foreign, Fas-mediated cyto-
toxicity seems to play a role in down-regulating
w ximmune responses 10,11 . In this instance, Fas–FasL
interactions may mediate the removal of the respond-
ing CTL population so that huge numbers of CTL do
not accumulate over time. Additionally, the tumour
necrosis factor receptor, which is related to Fas and
also contains a death domain, has been implicated in
the control of CTL number following an immune
w xresponse 12 .
2.3. Cytolytic proteins
As mentioned above, the cytolytic proteins reside
in the CTL granules, where they await exocytosis
towards a target cell. What are these proteins? The
first granule function-related protein identified was
the pore-forming protein perforin, which was shown
to be able to induce calcium-dependent lysis of target
w xcells 13–15 . In the granules, which are acidic,
perforin is found in monomeric form in association
with proteoglycans. Granule exocytosis releases per-
forin into the intracellular space where it is exposed
to both calcium and neutral pH. The neutral pH
causes the release of perforin monomers from proteo-
w xglycans 16 , allowing the monomers to bind the
w xlipids of the target cell membrane 17,18 . Perforin
then inserts into the cell membrane and aggregates in
a calcium-dependent manner to form a pore which
w xcan be seen by electron microscopy 19,20 . Since
perforin is able to cause lysis of a number of cell
types, it was originally believed that formation of the
perforin pore was sufficient to induce target cell
death. However, perforin alone cannot induce target
w xcell DNA fragmentation 21–23 , suggesting that per-
forin cannot mediate all of the events involved in
CTL-mediated cytotoxicity. It is now believed that
the primary function of perforin is not in cytolysis
but rather to allow other cytotoxic mediators to enter
the target cell.
The second set of cytolytic proteins identified were
the granzymes, a family of CTL-specific serine pro-
w xteases 24 which co-localise with perforin to the
w xgranules 25,26 . Although evidence is only just be-
ginning to accumulate regarding the roles of the
granzymes during CTL attack, it has been known for
some time that protease inhibitors can protect target
w xcells from cell-mediated lysis 27,28 . Furthermore,
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loading of cells with chymotrypsin, trypsin or pro-
teinase K has been found to cause cell lysis, accom-
panied in most cases by DNA fragmentation and
w xnuclear damage 29 . This suggests that proteases are
involved in the induction of target cell death and that
granzymes most likely exert their effect inside the
target cell, although this latter point awaits confirma-
tion.
An RNA-binding protein called TIA-1 has also
w xbeen localised to CTL granules 30 and has been
shown to induce DNA fragmentation in perme-
w xabilised cells 31 , suggesting a role for this protein in
target cell death. Interestingly, a related but ubiqui-
tously expressed protein called TIAR, has been found
to be translocated from the nucleus to the cytoplasm
in the target cell during Fas-mediated cytotoxicity
w x32 a conserved mechanism of inducing cell damage
between the Fas and granule killing pathways.
2.4. Target cell death
During both granule- and Fas-mediated cytotoxic-
ity, a target cell dies by undergoing a series of events
termed apoptosis. Apoptosis was originally described
as a morphological phenomenon occurring in two
w xdistinct phases 33,34 . In phase I, the cell’s cyto-
plasm condenses but ribosomal and mitochondrial
morphology is maintained. The chromatin condenses
and forms crescent-shaped aggregates lining the nu-
clear membrane, and the nucleolus fragments. During
this phase the cell’s DNA is fragmented into oligonu-
cleosomal-sized pieces. Eventually, the nucleus
breaks up into several fragments, the plasma mem-
brane invaginates and the cell separates into a num-
ber of membrane-bound fragments containing mor-
phologically normal mitochondria and other or-
ganelles. During phase II these ‘‘apoptotic bodies’’
are phagocytosed by neighbouring cells or by
macrophages.
Until recently, the biochemical events involved in
the induction of apoptosis, and how they are linked to
CTL-induced death, were unknown. Much of this
recent work has focused on a family of cysteine
proteases related to the mammalian interleukin-1b
 .converting enzyme ICE and the product of the
Caenorhabditis elegans ‘‘death gene’’ ced-3, and has
w xbeen reviewed elsewhere 35,36 . A number of
ICErCed-3 proteases have been identified and impli-
cated in cell death. These proteins are generated as
inactive precursors requiring proteolytic cleavage for
activation. Recently, a link was established between
apoptosis and CTL-mediated cytotoxicity by the find-
ing that granzyme B can cleave and activate a num-
w xber of ICErCed-3 proteases 37–46 . Furthermore,
this activity is directly related to the ability of
granzyme B to induce target cell DNA fragmentation
w x47,48 . ICErCed-3 proteases have also been impli-
w xcated in Fas-mediated killing 49–56 and, interest-
ingly, an ICErCed-3 protease has been found to
associate with the ‘‘death domain’’ of Fas following
w xreceptor oligomerisation 42,57 . It is believed that
recruitment of the protease to the oligomerised recep-
tor in some way results in protease activation. This
protease is then thought to initiate a cascade of events
 .resulting in target cell death Fig. 2 .
Thus, it seems that the CTL utilises a target cell’s
endogenous suicide program to induce target cell
apoptosis. However, some questions remain. Only
granzyme B has been shown to interact with the
apoptotic pathway and this mechanism seems to lead
Fig. 2. Target cell death. During granule-mediated cytotoxicity,
granzyme B enters the target cell, where it cleaves and activates
multiple ICErCed-3 proteases. In Fas-mediated killing, an
ICErCed-3 protease precursor interacts directly with oligomerised
receptors, resulting in protease activation. Once activated,
ICErCed-3 proteases cleave a number of cellular proteins, in-
 .cluding poly ADP-ribose polymerase DNA-dependent protein
kinase, the 70 kDa protein component of the U1 ribonucleopro-
tein particle, the cytoskeletal proteins actin, fodrin, Gas2, lamins,
the GDP dissociation inhibitor D4-GDI, the cell cycle proteins
retinoblastoma and the PITSLRE kinases, and the transcription
factors sterol regulatory element binding proteins. The end result
of ICErCed-3 protease activation is target cell death by apopto-
sis.
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predominantly to DNA fragmentation. How mem-
brane damage and cytolysis are induced, and the
exact roles of other cytolytic proteins such as
granzyme A and perforin, remains to be determined.
2.5. Serial killing
CTL are able to sustain their killing potential over
a period of time and are therefore capable of killing a
number of target cells. How is this accomplished? Do
they secrete all their granules and then rapidly re-
place them? Do they secrete only a portion of their
granules per recognised target cell? Or do CTL switch
between granule-mediated and Fas-mediated cytotox-
icity in order to maintain their cytotoxic potential?
It now seems clear that CTL maintain cytotoxic
potential through the same mechanisms which allow
them to be cytotoxic in the first place. As outlined
above, the initial recognition of a target cell through
the TcR triggers the synthesis of cytolytic proteins,
which are stored in the granules. Upon further inter-
action with a target cell, the CTL is triggered to
degranulate. However, concurrent with degranulation,
the CTL also synthesises new lytic proteins which
w xpresumably replenish the granules 58 . Surprisingly,
approximately 30% of these newly-synthesised pro-
teins are not stored in the granules, but rather are
constitutively secreted from the cell, which may ac-
count for some bystander lysis that is, killing of cells
.not specifically recognised by CTL . Since new syn-
thesis of lytic proteins is initiated in conjunction with
degranulation, this provides an excellent mechanism
by which serial killing may be accomplished. Addi-
tionally, FasL expression is also triggered by TcR
engagement, allowing this mechanism of killing to be
maintained across multiple targets.
Therefore, it seems that both granule- and Fas-
mediated killing are maintained throughout serial
killing as a direct result of TcR engagement. Thus, it
is unlikely that a CTL ‘‘switches’’ between killing
mechanisms in order to maintain cytolytic potential.
Rather, it is likely that each cytotoxic mechanism
serves a different purpose. That is, granule-mediated
killing is responsible for destroying specifically-re-
cognised foreign cells while Fas-mediated killing is
responsible for destroying self cells at the end of an
immune response.
3. The lytic granule as a lysosome
3.1. Lysosomal contents
The cytolytic proteins are not the only constituents
of lytic granules. Also present are proteins more
classically defined as lysosomal components, for ex-
ample, Cathepsins B and D, a-glucosidase, LAMP1
w xand LAMP2 59 . Lysosomes have a heterogeneous
morphology between cells and even within the same
cell type. Classically they have been defined as dense
organelles that contain acidic hydrolases which de-
grade intracellular components and macromolecules
w xthat have been endocytosed 60 . Both immunofluo-
resence and immuno-electron microscopic studies in-
dicate co-localisation of lysosomal and lytic proteins
in CTL, indicating that the lytic granules also func-
w xtion as lysosomes 61,62 .
3.2. Lytic granules are acidic compartments
Like lysosomes, the lytic granules of CTL are
w xacidic organelles 61–63 . Evidence for the presence
of a proton pump was provided when an inhibitor of
q  .vacuolar H -ATPase concanamycin A resulted in a
w xraised pH and altered granule morphology 64 . This
treatment also inhibits the cytolytic activity of the
CTL, demonstrating the importance of granule acid-
ification for CTL function.
Interestingly, the low pH of the granule only pro-
vides a favourable environment for the activity of the
 w x.lysosomal hydrolases localised there reviewed 65 .
The cytolytic proteins, perforin and granzymes, are
optimally active at a higher pH than that found in the
granule. Only upon granule exocytosis and the re-
lease of contents to the extracellular environment are
these proteins exposed to a more neutral pH at which
they are active. The storage of these proteins in an
acidic environment in which they are not active may
be one mechanism utilised by the cell to protect itself
against their lytic activity. Additionally, as described
in Section 2.3, the proteoglycan, Chondroitin sul-
phate A, which is a major component of granules,
interacts with both granzymes and perforin within the
w xgranule 66,67 . There is evidence that Chondroitin
sulphate A binds to and inhibits perforin in a pH
w xdependent manner 67 . Thus, this interaction is
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thought to maintain lytic proteins in an inactive state
while stored in the lytic granules.
Hence, the function of lytic granule content is
determined by pH: the granule itself maintains an
acidic pH thus allowing for the activity of lysosomal
hydrolases, while release of the lytic granule contents
into the neutral pH of the extracellular space by
exocytosis activates the cytolytic proteins.
3.3. The lytic granule as an endocytic compartment
One criterion of lysosomal function would be the
ability of lytic granules to receive and degrade endo-
cytosed macromolecules from the extracellular envi-
 .ronment see Fig. 3 . Delivery has indeed been ob-
 .served. Endocytosed cationized ferritin CF accumu-
lates in lytic granules with kinetics similar to that of
w xdelivery to lysosomes 61 . This uptake was also
sensitive to low temperatures which suggests that the
granule is a late compartment on the endocytic route.
The mature lytic granule does not contain the
 .mannose-6-phosphate receptor M6PR , a protein as-
sociated with endosomes but not with lysosomes see
.Fig. 3 and Section 4.1 . Although granule proteins,
synthesised in newly activated CTL, are initially
found in a compartment that is M6PR positive, at a
later stage in the biogenesis of the organelle they are
found to be present in a M6PR negative compart-
ment. This observation also implies that the lytic
proteins are present in a compartment late in the
endocytic pathway.
Thus, the data suggest that the lytic granule can
perform two functions for the CTL that are, in other
cell types, usually carried out by two distinct or-
 .Fig. 3. Biosynthetic and endocytic pathways. Newly synthesised proteins are transported from the endoplasmic reticulum ER through
 .the Golgi to the trans Golgi network TGN . During this transportation, soluble lysosomal proteins aquire a mannose-6-phosphate tag
 .which enables association with the mannose-6-phosphate receptor M6PR . At the TGN, both receptor and ligand are selectively included
into clathrin coated vesicles and are transported to a pre-lysosomal compartment. The ligand dissociates from the receptor in this
compartment, allowing the M6PR to recycle back to the TGN. Extracellular macromolecules, which bind to receptors at the plasma
membrane that are specifically included into clathrin coated vesicles, are endocytosed and transported to an early endosome. From there,
proteins can either recycle back to the plasma membrane or continue on along a pathway to the lysosome.
( )L.J. Page et al.rBiochimica et Biophysica Acta 1401 1998 146–156152
ganelles. The lysosomes of CTLs are therefore not
only involved in internal degradation events but,
uniquely, can be exocytosed as a regulated event to
allow secretion of contents whose function is to
destroy infectedrcancerous cells.
4. Lytic granules as secretory organelles
In addition to the mechanisms that are needed to
accomplish this ‘‘double life’’ of the lytic granules
outlined earlier, a CTL must be able to target both
newly synthesised lysosomal and cytolytic proteins to
the same compartment. This is very different from
the situation in ‘‘conventional’’ secretory cells, where
lysosomal and secretory proteins are sorted to differ-
ent organelles which maintain separate functions.
4.1. Sorting of lysosomal proteins
For soluble proteins, two distinct pathways for
sorting to the lytic granules have been described. The
major pathway responsible for targeting of soluble
lysosomal hydrolases to the lysosome utilises the
 . w xmannose-6-phosphate-receptor M6PR 68 . Proteins
destined for the lysosome are covalently modified by
 .the addition of mannose-6-phosphate M6P groups
to their N-linked glycans in the cis-Golgi network.
The phosphotransferase that catalyses this reaction
recognises a specific signal in the polypeptide chain
of each lysosomal hydrolases. Although this signal
w xhas been defined for some hydrolases 69 , there is no
simple motif that is shared between the different
hydrolases. Proteins that have acquired the M6P tag
are able to interact with the transmembrane M6PR in
w xthe TGN 70 . Both receptor and ligand enter into
clathrin coated vesicles and are thus, selectively
transported to a prelysosome compartment. Exposure
to the low pH of the prelysosome results in the
dissociation of lysosomal hydrolases from the M6PR,
which can then recycle back to the TGN.
However, delivery of lysosomal proteins is not
solely dependent on M6P-tagging and M6PR. A
M6PR-independent route also exists. Studies on cells
derived from patients with I-cell disease mucolipido-
.sis II have shown that lysosomal hydrolases can still
reach the lysosome in these cells despite the fact that
none of the hydrolases acquire the M6P modification.
In I-cell disease, the phosphotransferase responsible
for the phosphorylation of mannose residues is absent
or defective. Consequently, lysosomal proteins do not
acquire the M6P group and are not, therefore, trans-
ported to the lysosome by the M6PR. Instead, they
appear to be secreted from the cells via the constitu-
tive pathway. Thus, the observation that a fraction of
lysosomal enzymes are present in lysosomes suggests
that, in addition to the well characterised M6PR
pathway, an alternative, M6PR-independent route to
w xthe lysosome also exists 69 .
In contrast to the soluble lysosomal proteins, the
transport of integral membrane proteins to lysosomes
does not involve the M6PR. Instead, the cytoplasmic
tail of these proteins is necessary for their delivery to
the lysosome. Two types of signal have been defined
which are able to mediate targeting to the lysosomes,
a tyrosine based signal and a di-leucine based motif
 w x.reviewed by W. Hunziker and H. Geuze, 71 .
These two lysosomal sorting signals have also been
identified in the lytic granule proteins of CTL, such
as T1A, CD3g and d chains of the TCR and CD63.
The tyrosine based motif has been shown to interact
with the clathrin-associated protein complexes AP1
and AP2, indicating that clathrin coated vesicles are
used for the transportation of these lytic granule
w xproteins 72 .
4.2. Sorting of granzymes and perforin
How are the soluble secretory proteins, granzymes
and perforin, sorted to the lytic granules? In conven-
tional secretory cells, the secretory proteins are sorted
by a selective aggregation in the TGN, which results
in the segregation of these proteins to a distinct
w xorganelle 73 .
The sorting mechanism of granzymes became clear
from studies on CTL derived from patients with I-cell
disease. In these cells, granzymes A and B were not
correctly sorted, but were secreted constitutively. This
suggested that granzymes A and B were normally
targeted to the granules by the M6PR pathway, and
that in I-cells, where the M6P is not added, the
granzymes cannot be sorted correctly. Biochemical
data confirmed this, demonstrating that granzymes do
w xin fact bear M6P residues in wild type cells 74 .
Nevertheless, approximately 20% of the granzymes
in I-cells are still properly localised to the lytic
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granules, indicating that granzymes can also use an
M6PR-independent pathway. Whether this M6PR-in-
dependent pathway is the same as that used by the
lysosomal hydrolases remains to be determined.
Although perforin is also a soluble secreted pro-
tein, it is not sorted to the lytic granules by the
w xmannose-6-phosphate receptor. Neither rat 75 nor
w xhuman 76 perforin acquire a M6P modification
during their biosynthesis, excluding the possibility of
sorting via this route. The observation that I-cell CTL
are able to lyse target cells with the same efficiency
as wild-type CTL supports the idea that perforin is
targeted normally in these cells, and that only MPR-
independent mechanisms are responsible for correct
w xpackaging and secretion of perforin 74 .
5. Secretory lysosomes in the haemopoietic lineage
5.1. Other cell types with secretory lysosomes
The lytic granules of CTL and NK cells exhibit all
the characteristics of conventional lysosomes. In ad-
dition, lytic granules are able to fuse with the plasma
membrane and undergo regulated exocytosis acting
 w x.as secretory organelles reviewed in 77 . For a CTL,
this process of secretion is of crucial importance to
it’s function because this is how the cytotoxic pro-
teins perforin and granzymes, which are stored in the
lytic granules, get to their site of action.
Secretory lysosomes are not unique to cytotoxic T
lymphocytes but are found in other cells types, for
example eosinophils, neutrophils, basophils, platelets,
 w x.mast cells and macrophages reviewed 77 . Interest-
ingly, these cells all belong to the same lineage, the
haemopoietic lineage. This introduces the possibility
that these cells express lineage specific proteins that
are responsible for the regulated exocytosis of their
lysosome. Thus, it might be expected to find lineage
specific expression of proteins that have a role in, for
example, membrane recognition and fusion, such as
v- and t-SNARES, rabs or perhaps a protein that acts
as a calcium sensor to regulate secretion such as the
role proposed for synaptotagmin in neurons. Recent
work has demonstrated that lysosomes in fibroblasts
can also undergo exocytosis in response to a calcium
w xflux generated by ionomycin 78 . This work suggests
that lysosome fusion with the plasma membrane may
be possible in all cell types perhaps providing a
.mechanism for membrane repair . The haemopoietic
lineage may have exploited this ability to undergo
membrane fusion to generate a regulated secretory
organelle.
5.2. Chediak Higashi Syndrome
The recessive, human genetic defect that results in
 .Chediak Higashi Syndrome CHS in homozygous
patients may provide information on how these spe-
cialised cells allow lysosome secretion. Although this
defect affects most cells, resulting in enlarged lyso-
somes, in non-haemopoietic cells there does not ap-
pear to be any functional impairment. However, in
haemopoietic cells secretion of lysosomes no longer
w xoccurs 79 . There are several possibilities for the
nature of this genetic defect since multiple steps are
required for secretion to proceed. Firstly, the T cell
 .receptor TcR signalling pathway has to be activated
in order to produce the increase in internal Ca2q
concentration required for exocytosis of the secretory
lysosome. TcR signalling is functional, at least to
some extent, since resting CHS cells can be triggered
via the TcR to proliferate and develop into mature
cells. The next event to occur is movement of the
granule towards the plasma membrane, so that it is
close to the point of contact with the target cell. This
process is dependent on microtubules. Work by Perou
w xand Kaplan 80 indicates however, that there is no
microtubule associated defect in CHS fibroblasts.
Polarisation of CHS granules against the plasma
membrane at the site of contact with the target cell
has been observed at IF level unpublished observa-
.tion , however, a more detailed study with electron
microscopy is required. It is possible that the large
size of the mutant secretory granule simply hinders
its movement through the cytoplasm thus preventing
its contact and therefore fusion with the plasma mem-
brane. Certainly, experiments where macrophages
were fed beads of various sizes to increase the size of
the lysosome indicated that the larger the bead inter-
w xnalised, the more static the organelle was 80 . How-
ever, an argument against this comes from the obser-
vation that CHS mast cells can be stimulated to
2q w xsecrete by using a Ca ionophore 81 .
The last step of secretion is fusion of the granule
with the plasma membrane. Since an abnormally
( )L.J. Page et al.rBiochimica et Biophysica Acta 1401 1998 146–156154
large organelle is formed in the mutant cells, it has
been proposed that a membrane fusion event may be
affected. Interestingly, during the biogenesis of the
secretory organelle in newly stimulated CHS cells,
there are initially ;50 M6PR positive granules per
cell and these cells look identical to wild type cells.
However, as the CHS cell matures, the number of
granules decreases to about 1–3 M6PR negative
granules per cell, in contrast to wild type cells where
the initial number is maintained L.J.P. and G.M.G.,
.unpublished observation . This suggests that as ma-
ture lysosomes are formed they fuse to produce fewer,
but larger organelles.
The gene responsible for the defect has now been
w xidentified 82,83 . The gene encodes several alterna-
tively spliced products encoding proteins predicted to
be in the range of 200 kDa. The gene shows no
regions of strong homology to other sequences, and
gives no clue as to it’s role in secretion.
6. Summary and conclusion
CTL are important cells in the immune system
which are able to recognise and directly destroy
virally infected, tumorigenic or foreign cells. The
proteins which mediate this destruction are packaged
into specialised secretory granules, termed lytic gran-
ules, which are secreted in response to target cell
recognition. Curiously these specialised secretory
granules also contain all the lysosomal hydrolases,
and in CTL the lytic granules serve two separate
functions: as a lysosome within the cell, and as a
secretory granule when a target cell is recognised.
These ‘‘secretory lysosomes’’, which serve impor-
tant roles in both protein degradation within the cells
as well as regulated secretion of proteins from the
cells, are also found in other cell types, all of which
are derived from the hemopoietic lineage. This obser-
vation raises the possibility that cells of the hemopoi-
etic lineage possess specialised sorting and secretory
mechanisms which allow the lysosomes to be used as
secretory organelles. Studies on Chediak Higashi syn-
drome support this idea, since in this naturally occur-
ring genetic mutation, cells with secretory lysosomes
are unable to secrete their granules while other con-
ventional secretory cells are able to do so. Further
studies on the mechanisms which regulate secretion
of lytic proteins from CTL should identify the pro-
teins involved in this unusual secretory pathway.
Some aspects of the differences between conven-
tional and ‘‘secretory’’ lysosomes remain unresolved.
How the biogenesis of the secretory lysosome differs
from that of a conventional secretory granule is un-
clear. While conventional secretory cells sort proteins
destined for the granule by a selective condensation
in the TGN, the secretory lysosomes seem to use a
combination of lysosomal and other sorting signals.
Our preliminary studies suggest that haemopoietic
cells possess specialised sorting mechanisms which
allow the correct sorting of the secreted products to
the lysosome, and that these signals are different
from those found in conventional secretory e.g. neu-
.rosecretory cells. This finding and the observation
that fibroblast lysosomes can undergo calcium-media-
ted exocytosis suggests that the unusual secretory
system found in haemopoietic cells may be a result of
specialised sorting mechanisms in these cells. In this
case the Chediak lesion may turn out to be a sorting
defect.
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